Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.

Thomas Powles,Jonathan E. Rosenberg,Guru Sonpavde,Yohann Loriot,Ignacio Duran,Jae-Lyun Lee,Nobuaki Matsubara,Christof Vulsteke,Chunzhang Wu,Mary S. Campbell,Maria Matsangou,Daniel P. Petrylak

Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.

2021

Thomas Powles
Jonathan E. Rosenberg
Guru Sonpavde
Yohann Loriot
Ignacio Duran
Jae-Lyun Lee
Nobuaki Matsubara
Christof Vulsteke
Chunzhang Wu
Mary S. Campbell
Maria Matsangou
Daniel P. Petrylak

393Background: Patients with locally advanced or metastatic urothelial carcinoma (la/mUC) have poor survival following progression after platinum-containing chemotherapy and PD-1/L1 inhibitor regim...

Keywords:

locally advanced
Metastatic Urothelial Carcinoma
Oncology
previously treated
in patient
Internal medicine
Enfortumab vedotin
Chemotherapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations